Prise en Charge Médicale des Personnes Vivant Avec le VIH. Recommandations du Groupe D'experts. Rapport, p.476, 2013. ,
Causes of death among HIV-infected patients in France in 2010 (national survey): trends since, AIDS, vol.28, pp.1181-1191, 2000. ,
Association of cancer with AIDS-related immunosuppression in adults, JAMA, vol.285, pp.1736-1745, 2001. ,
Spectrum of AIDS-associated malignant disorders, Lancet, vol.351, pp.1833-1839, 1998. ,
The tumor virus landscape of AIDSrelated lymphomas, Blood, vol.125, pp.14-22, 2015. ,
Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034, J Clin Oncol, vol.27, pp.5039-5048, 2009. ,
Epstein-Barr virus infection and expression of B-cell oncogenic markers in HIV-related diffuse large B-cell Lymphoma, Clin Cancer Res, vol.18, pp.4702-4712, 2012. ,
Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis, Lancet, vol.370, pp.59-67, 2007. ,
A meta-analysis of the incidence of nonAIDS cancers in HIV-infected individuals, J Acquir Immune Defic Syndr, vol.52, pp.611-622, 2009. ,
AIDS-related malignancies: state of the art and therapeutic challenges, J Clin Oncol, vol.26, pp.4834-4842, 2008. ,
British HIV Association guidelines for HIV-associated malignancies 2014, HIV Med, vol.15, pp.1-92, 2014. ,
Optimal management of cervical cancer in HIV-positive patients: a systematic review, Cancer Med, vol.4, pp.1381-1393, 2015. ,
Consensus of the Brazilian Society of Infectious Diseases and Brazilian Society of Clinical Oncology on the management and treatment of Kaposi's sarcoma, Braz J Infect Dis, vol.18, pp.315-326, 2014. ,
Therapy of HIV-associated lymphomarecommendations of the Oncology Working Group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNA), in cooperation with the German AIDS Society (DAIG), Ann Hematol, vol.93, pp.913-921, 2014. ,
Management of HIV infection in patients with cancer receiving chemotherapy, Clin Infect Dis, vol.59, pp.106-114, 2014. ,
Age at cancer diagnosis among persons with AIDS in the United States, Ann Intern Med, vol.153, pp.452-460, 2010. ,
Cancer Risk Group of the French Hospital Database on HIV. Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort, AIDS, vol.28, pp.2109-2118, 2014. ,
The aging of the HIV epidemic, Curr HIV/ AIDS Rep, vol.5, pp.150-158, 2008. ,
Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions, Clin Infect Dis, vol.47, pp.542-553, 2008. ,
Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to, Cancer, vol.116, pp.5507-5516, 2007. ,
Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the French Hospital Database on HIV, J Clin Oncol, vol.30, pp.4360-4366, 2012. ,
Changing patterns of cancer incidence in the early-and late-HAART periods: the Swiss HIV Cohort Study, Br J Cancer, vol.103, pp.416-422, 2010. ,
Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study, Lancet Oncol, vol.10, pp.1152-1159, 2009. ,
Chapter 6: immunosuppression and co-infection with HIV, J Natl Cancer Inst Monogr, pp.41-46, 2003. ,
HIV infection, immunodeficiency, viral replication, and the risk of cancer, Cancer Epidemiol Biomarkers Prev, vol.20, pp.2551-2559, 2011. ,
Elevated incidence of lung cancer among HIV-infected individuals, J Clin Oncol, vol.24, pp.1383-1388, 2006. ,
Elevated risk of lung cancer among people with AIDS, AIDS, vol.21, pp.207-213, 2007. ,
HIV infection is associated with an increased risk for lung cancer, independent of smoking, Clin Infect Dis, vol.45, pp.103-110, 2007. ,
Risk of cancer among HIV-infected individuals compared to the background population: impact of smoking and HIV, AIDS, vol.28, pp.1499-1508, 2014. ,
Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer, J Natl Cancer Inst, vol.103, pp.1112-1122, 2011. ,
Tobacco smoking increases immune activation and impairs T-cell function in HIV infected patients on antiretrovirals: a cross-sectional pilot study, PLoS One, vol.9, p.97698, 2014. ,
, Guideline on When to Start Antiretroviral Therapy and on pre-Exposure Prophylaxis for HIV, Data WLC-i-P Edition, 2015.
Tobacco smoking in HIV-infected versus general population in France: heterogeneity across the various groups of people living with HIV, PLoS One, vol.9, p.107451, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01369609
Treatment of tobacco use in lung cancer: diagnosis and management of lung cancer, Chest, vol.143, pp.61-77, 2013. ,
Lung cancer in HIV infection, Clin Lung Cancer, vol.13, pp.6-13, 2012. ,
Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care, J Acquir Immune Defic Syndr, vol.43, pp.47-55, 2006. ,
Human immunodeficiency virusassociated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration, Clin Lung Cancer, vol.11, pp.396-404, 2010. ,
Effect of HIV on survival in patients with nonsmall-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study, Lancet Oncol, vol.13, pp.1203-1209, 2012. ,
HIV as an independent risk factor for incident lung cancer, AIDS, vol.26, pp.1017-1025, 2012. ,
Cancer treatment disparities in HIV-infected individuals in the United States, J Clin Oncol, vol.32, pp.2344-2350, 2014. ,
Elevated cancer-specific mortality among HIV-infected patients in the United States, J Clin Oncol, vol.33, pp.2376-2383, 2015. ,
Trends in survival after cancer diagnosis among HIV-infected individuals between 1992 and 2009. Results from the FHDH-ANRS CO4 cohort, Int J Cancer, vol.137, pp.2443-2453, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01166935
ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease, Ann Oncol, vol.25, pp.1475-1484, 2014. ,
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.24, issue.6, pp.89-98, 2013. ,
Human immunodeficiency virus infection and non-small cell lung cancer: survival and toxicity of antineoplastic chemotherapy in a cohort study, J Thorac Oncol, vol.6, pp.1022-1029, 2011. ,
Use of antineoplastic agents in patients with cancer who have HIV/AIDS, Lancet Oncol, vol.12, pp.905-912, 2011. ,
Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib, Cancer Chemother Pharmacol, vol.76, pp.813-819, 2015. ,
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N Engl J Med, vol.373, pp.123-135, 2015. ,
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, vol.373, pp.1627-1639, 2015. ,
Reduced lung-cancer mortality with low-dose computed tomographic screening, N Engl J Med, vol.365, pp.395-409, 2011. ,
Feasibility and efficacy of early lung cancer diagnosis with chest computed tomography in HIV-infected smokers. The ANRS EP48 HIV CHEST Study, AIDS, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01274227
Prospective CT screening for lung cancer in a high-risk population: HIV-positive smokers, J Thorac Oncol, vol.9, pp.752-759, 2014. ,
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study, J Hepatol, vol.47, pp.527-537, 2007. ,
Standardized care management ensures similar survival rates in HIV-positive and HIV-negative patients with hepatocellular carcinoma, J Acquir Immune Defic Syndr, vol.61, pp.581-587, 2012. ,
American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update, Hepatology, vol.53, pp.1020-1022, 2011. ,
, European Association For The Study of The L, European Organisation For R, Treatment of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma, J Hepatol, vol.56, pp.908-943, 2012.
Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis ,
, Ann Oncol, vol.23, issue.7, pp.41-48, 2012.
British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013, HIV Med, vol.14, issue.4, pp.1-71, 2013. ,
Hepatocellular carcinoma in HIV patients treated by liver transplantation, Eur J Surg Oncol, vol.34, pp.422-427, 2008. ,
Human immunodeficiency virus and liver transplantation: our point of view, Transplant Proc, vol.40, pp.1965-1971, 2008. ,
Multicenter Italian experience in liver transplantation for hepatocellular carcinoma in HIV-infected patients, Oncologist, vol.18, pp.592-599, 2013. ,
Hepatocellular carcinoma in HIVinfected patients: check early, treat hard, Oncologist, vol.16, pp.1258-1269, 2011. ,
Liver transplantation for hepatocellular carcinoma: the impact of human immunodeficiency virus infection, Hepatology, vol.53, pp.475-482, 2011. ,
Hepatocellular carcinoma in HIV positive patients, Eur Rev Med Pharmacol Sci, vol.16, pp.1257-1270, 2012. ,
Do the epidemiology, physiological mechanisms and characteristics of hepatocellular carcinoma in HIVinfected patients justify specific screening policies?, AIDS, vol.28, pp.1379-1391, 2014. ,
Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients, Anticancer Drugs, vol.24, pp.212-218, 2013. ,
Suspected interaction between sorafenib and HAART in an HIV-1 infected patient: a case report, Hepatogastroenterology, vol.58, pp.161-162, 2011. ,
Epidermoid anal cancer prognosis comparison among HIV+ and HIV-patients, Aliment Pharmacol Ther, vol.30, pp.414-421, 2009. ,
Human papillomavirus genotype distribution in anal cancer in France: the EDiTH V study, Int J Cancer, vol.129, pp.433-439, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00563122
Multiple human papillomavirus infections are highly prevalent in the anal canal of human immunodeficiency virus-positive men who have sex with men, BMC Infect Dis, vol.14, p.671, 2014. ,
Anal carcinoma in human immunodeficiency virus-positive men: results of a prospective study from Germany, Br J Dermatol, vol.162, pp.1269-1277, 2010. ,
Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men, AIDS, vol.19, pp.1407-1414, 2005. ,
Malignant progression of anal intraepithelial neoplasia, ANZ J Surg, vol.76, pp.715-717, 2006. ,
Treatment of HIV-associated invasive anal cancer with combined chemoradiation, Eur J Cancer, vol.36, pp.754-758, 2000. ,
Outcome of HIV-infected patients with invasive squamous-cell carcinoma of the anal canal in the era of highly active antiretroviral therapy, Dis Colon Rectum, vol.47, pp.1305-1309, 2004. ,
Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy, Dis Colon Rectum, vol.51, pp.73-81, 2008. ,
HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy, J Clin Oncol, vol.26, pp.2550-2557, 2008. ,
Outcomes of chemoradiotherapy with 5Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients, Int J Radiat Oncol Biol Phys, vol.75, pp.143-149, 2009. ,
HIV and anal cancer outcomes: a single institution's experience, Dis Colon Rectum, vol.52, pp.891-897, 2009. ,
Economic burden of anal cancer management in France, Rev Epidemiol Sante Publique, vol.58, pp.331-338, 2010. ,
Concurrent chemoradiotherapy with 5fluorouracil and mitomycin C for invasive anal carcinoma in human immunodeficiency virus-positive patients receiving highly active antiretroviral therapy, Int J Radiat Oncol Biol Phys, vol.76, pp.1425-1432, 2010. ,
Anal carcinoma in HIV-infected patients in the era of antiretroviral therapy: a comparative study, Dis Colon Rectum, vol.54, pp.729-735, 2011. ,
,
, Bull Cancer, vol.101, pp.1034-1039, 2014.
Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.21, issue.5, pp.87-92, 2010. ,
Salvage surgery for residual primary and locally recurrent anal squamous cell carcinoma after chemoradiotherapy in HIVpositive individuals, Ann Surg Oncol, vol.21, pp.527-532, 2014. ,
5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer, Bull Cancer, vol.86, pp.861-865, 1999. ,
Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal, Am J Clin Oncol, vol.16, pp.536-540, 1993. ,
Prevalence of HIV infection among U. S. Hodgkin lymphoma cases, Cancer Epidemiol Biomarkers Prev, vol.23, pp.274-281, 2014. ,
High risk features contrast with favorable outcomes in HIV-associated Hodgkin lymphoma in the modern cART era, ANRS CO16 LYMPHOVIR Cohort, Clin Infect Dis, vol.61, pp.1469-1475, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01543677
Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study, J Clin Oncol, vol.30, pp.4117-4123, 2012. ,
HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era, J Clin Oncol, vol.30, pp.4111-4116, 2012. ,
How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus, Blood, vol.125, pp.1226-1235, 2015. ,
Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma, Haematologica, vol.92, pp.191-198, 2007. ,
Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study, Cancer, vol.121, pp.423-431, 2015. ,
High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)related lymphoma: results and impact on HIV disease, Haematologica, vol.89, pp.1100-1108, 2004. ,
Brentuximab vedotin in patients with relapsed HIV-related lymphoma, J Natl Compr Canc Netw, vol.12, pp.16-19, 2014. ,
, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services, 2015.
guidelines for antiretroviral therapy of HIV-1 infection in adults, J Int AIDS Soc, vol.17, 2013. ,
, European Aids Clinical Society Guidelines In Edition Version 7.1. European AIDS Clinical Society, 2014.
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial, Ann Intern Med, vol.161, pp.461-471, 2014. ,
Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial, Lancet, vol.384, pp.1942-1951, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01108186
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study, Lancet, vol.383, pp.2222-2231, 2014. ,
Targeted therapies to treat non-AIDSdefining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook, Curr Opin Oncol, vol.21, pp.445-454, 2009. ,
Drug interactions with new and investigational antiretrovirals, Clin Pharmacokinet, vol.48, pp.211-241, 2009. ,
Pharmacokinetics and drug-drug interactions of antiretrovirals: an update, Antiviral Res, vol.85, pp.176-189, 2010. ,
Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi's sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial, Cancer Chemother Pharmacol, vol.68, pp.827-833, 2011. ,
Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma, Clin Pharmacol Ther, vol.83, pp.601-606, 2008. ,
A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061, Cancer, vol.120, pp.1194-1202, 2014. ,
Orchestrating immune check-point blockade for cancer immunotherapy in combinations, Curr Opin Immunol, vol.27, pp.89-97, 2014. ,
DOI : 10.1016/j.coi.2014.01.002
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial, Lancet Oncol, vol.15, pp.69-77, 2014. ,
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD1 therapy, Clin Cancer Res, vol.20, pp.5064-5074, 2014. ,
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression, Nature, vol.443, pp.350-354, 2006. ,
DOI : 10.1038/nature05115
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction, Nat Med, vol.12, pp.1198-1202, 2006. ,